Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

DANIEL KEIZMAN
* ,
Moshe Frenkel
ORCID logo ,
Avivit Peer
,
Eli Rosenbaum
,
David Sarid
,
Ilan Leibovitch
,
Roy Mano
,
Ofer Yossepowitch
,
Ido Wolf
ORCID logo ,
Ravit Geva
ORCID logo ,
David Margel
,
Keren Rouvinov
,
Anat Stern
,
Hadas Dresler
,
Igal Kushnir
,
Isaac Eliaz
Version 1 : Received: 6 July 2023 / Approved: 7 July 2023 / Online: 7 July 2023 (10:29:02 CEST)

A peer-reviewed article of this Preprint also exists.

Keizman, D.; Frenkel, M.; Peer, A.; Rosenbaum, E.; Sarid, D.; Leibovitch, I.; Mano, R.; Yossepowitch, O.; Wolf, I.; Geva, R.; Margel, D.; Rouvinov, K.; Stern, A.; Dresler, H.; Kushnir, I.; Eliaz, I. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study. Nutrients 2023, 15, 3533. Keizman, D.; Frenkel, M.; Peer, A.; Rosenbaum, E.; Sarid, D.; Leibovitch, I.; Mano, R.; Yossepowitch, O.; Wolf, I.; Geva, R.; Margel, D.; Rouvinov, K.; Stern, A.; Dresler, H.; Kushnir, I.; Eliaz, I. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study. Nutrients 2023, 15, 3533.

Abstract

The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol® modified citrus pectin (P-MCP) is a food supplement generally recognized as safe (GRAS) by the Food and Drug Administration (FDA) and is a competitive inhibitor of galectin-3 protein, involved in cancer pathogenesis. P-MCP treatment of BRPC-M0 patients for 6 months led to a 75% prostate-specific antigen doubling time (PSADT) improvement. To determine the longer-term effects of P-MCP we investigated an additional 12 months of treatment (phase II) with oral P-MCP at 4.8 grams X 3/day in patients with no disease progression in the previous 6 months. Of the 46 patients that entered the second phase, 7 patients withdrew consent and continued therapy independently, and 39 received another 12 months of therapy. After a total of 18 months P-MCP treatment, 62% (n=24) had a decreased/stable PSA, 90% (n=35) had improved PSADT, and 85% (n=33) had a durable long-term response, with a decreased/stable PSA, and/or improvement of PSADT, and negative scans. No patient had grade 3/4 toxicity. In conclusion, P-MCP may have long term durable efficacy, and is safe, in BRPC-M0.

Keywords

modified citrus pectin; non-metastatic biochemically relapsed prostate cancer

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.